Bone Biologics reports NB1 clinical trial progress: 3 sites engaged in Australia

Bone Biologics Corp

NB1 pilot trial: 30 adults, randomized, evaluating safety & effectiveness in TLIF for DDD.
Three Australian hospital sites engaged after HREC approval; study design reviewed by FDA.
Inclusion: DDD at one level L2-S1, up to Grade 1 spondylolisthesis or retrolisthesis.
Progress supports advancement toward potential US pivotal trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.